Search

Your search keyword '"Carotid Stenosis economics"' showing total 4 results
Start Over Descriptor "Carotid Stenosis economics" Publisher sage
4 results on '"Carotid Stenosis economics"'

1. Why the United States Center for Medicare and Medicaid Services should not extend reimbursement indications for carotid artery angioplasty/stenting.

Author

Abbott AL, Adelman MA, Alexandrov AV, Barnett HJ, Beard J, Bell P, Björck M, Blacker D, Buckley CJ, Cambria RP, Comerota AJ, Sander Connolly E, Davies AH, Eckstein HH, Faruqi R, Fraedrich G, Gloviczki P, Hankey GJ, Harbaugh RE, Heldenberg E, Kittner SJ, Kleinig TJ, Mikhailidis DP, Moore WS, Naylor R, Nicolaides A, Paraskevas KI, Pelz DM, Prichard JW, Purdie G, Ricco JB, Riles T, Rothwell P, Sandercock P, Sillesen H, David Spence J, Spinelli F, Tan A, Thapar A, Veith FJ, and Zhou W

Subjects
Angioplasty adverse effects, Angioplasty instrumentation, Asymptomatic Diseases, Carotid Stenosis diagnosis, Evidence-Based Medicine economics, Humans, Patient Selection, Risk Assessment, Risk Factors, Severity of Illness Index, United States, Angioplasty economics, Carotid Stenosis economics, Carotid Stenosis therapy, Centers for Medicare and Medicaid Services, U.S. economics, Health Care Costs, Insurance, Health, Reimbursement, Stents economics
Published
2012
Full Text
View/download PDF

2. Should Medicare reimbursement for carotid artery stenting be extended to standard and low risk symptomatic and asymptomatic patients with carotid stenosis?

Author

Gray WA, Macdonald S, and Schneider PA

Subjects
Angioplasty adverse effects, Angioplasty instrumentation, Asymptomatic Diseases, Carotid Stenosis diagnosis, Evidence-Based Medicine economics, Humans, Patient Selection, Risk Assessment, Risk Factors, Severity of Illness Index, United States, Angioplasty economics, Carotid Stenosis economics, Carotid Stenosis therapy, Health Care Costs, Insurance, Health, Reimbursement, Medicare economics, Stents economics
Published
2012
Full Text
View/download PDF

3. CMS considers expanding reimbursement for carotid stenting.

Author

Veith FJ

Subjects
Angioplasty adverse effects, Angioplasty instrumentation, Asymptomatic Diseases, Carotid Stenosis diagnosis, Evidence-Based Medicine economics, Humans, Patient Selection, Risk Assessment, Risk Factors, Severity of Illness Index, United States, Angioplasty economics, Carotid Stenosis economics, Carotid Stenosis therapy, Centers for Medicare and Medicaid Services, U.S. economics, Health Care Costs, Insurance, Health, Reimbursement, Stents economics
Published
2012
Full Text
View/download PDF

4. Are symptomatic patients appropriate candidates for carotid artery stenting? No (at least not at present).

Author

Paraskevas KI, Mikhailidis DP, and Veith FJ

Subjects
Angioplasty adverse effects, Angioplasty economics, Carotid Stenosis complications, Carotid Stenosis economics, Carotid Stenosis surgery, Cost-Benefit Analysis, Health Care Costs, Humans, Recurrence, Risk Assessment, Risk Factors, Stroke etiology, Stroke prevention & control, Treatment Outcome, Angioplasty instrumentation, Carotid Stenosis therapy, Endarterectomy, Carotid adverse effects, Endarterectomy, Carotid economics, Patient Selection, Stents
Abstract

Most symptomatic patients should not be candidates for carotid artery stenting (CAS); at least not at present. In these patients, CAS is associated with higher stroke, as well as recurrent stenosis rates compared with carotid endarterectomy (CEA). Furthermore, CAS is considerably more expensive than CEA. These facts raise the question, why perform CAS in symptomatic patients when you have CEA, which is associated with lower stroke and recurrent stenosis rates, and is also a more cost-effective option. This article supports the theory that currently most symptomatic patients are not appropriate candidates for CAS.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results